Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSTAGE: nintedanib with or without sildenafil in idiopathic pulmonary fibrosis with advanced lung function impairment
2015-002619-14Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing nintedanib + sildenafil with nintedanib alone (2 arms). Primary endpoint: Change from baseline in St George's Respiratory Questionnaire total score at week 12. Started May 2016; status: completed.
02
Drugs
nintedanibsildenafil
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2015-002619-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002619-14.